No­var­tis is send­ing 500 jobs to the scrap heap while adding 350 ‘high-tech’ po­si­tions for growth

No­var­tis is tak­ing out the ax again in its on­go­ing glob­al re­or­ga­ni­za­tion, cut­ting in­to its R&D group while mak­ing room for hun­dreds of new hires. Fol­low­ing an over­haul that was fo­cused on the US and Asia last year, it’s the Basel cam­pus that’s get­ting a makeover now.

Up to 500 jobs in No­var­tis’ drug de­vel­op­ment, “tra­di­tion­al” man­u­fac­tur­ing and co­or­di­na­tion group are be­ing scrapped, with the staffers ei­ther be­ing laid off, re­tir­ing ear­ly or mov­ing to oth­er lo­ca­tions. Mov­ing in­to the com­pa­ny will be 350 new em­ploy­ees for “high-tech” po­si­tions in Switzer­land, al­so for drug de­vel­op­ment as well as “in­no­v­a­tive” bi­o­log­ics man­u­fac­tur­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER